Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Identifying Correlates of Brain Microglial Activation in Neuropsychiatric Syndromes: A Dimensional Approach

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03705715
Recruitment Status : Recruiting
First Posted : October 15, 2018
Last Update Posted : October 5, 2021
Sponsor:
Information provided by (Responsible Party):
Alan Prossin, The University of Texas Health Science Center, Houston

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this research is to determine whether there is more extensive inflammation in the brain of people with clinical evidence of neuropsychiatric syndromes, such as mood disorder, chronic pain syndrome, dementia, traumatic brain injury, or substance abuse. The research will also explore whether there is more inflammation in patients with more neuropsychiatric symptoms. Inflammation in the brain will identified by using Positron Emission Tomography (PET) with the radiotracer [11C]PBR-28 or [11C]ER176.

Condition or disease Intervention/treatment Phase
Neuropsychiatric Syndromes Drug: PET with radiotracer [11C]PBR-28 ( or [11C]ER176) Other: Affective challenge Phase 1

Detailed Description:

This study will explore whether brain microglial activation (which leads to an inflammatory response) is more extensive in individuals with clinical evidence of neuropsychiatric syndromes and whether the extent of microglial activation is proportional to the extent of neuropsychiatric symptoms.

More specifically, the hypothesis is that:

  1. Brain microglial activation is more substantial in the presence of neuropsychiatric illness, and the extent of brain microglial activation is proportional to severity of phenotypic presentation of neuropsychiatric illness (i.e. depression, cognitive impairment, fatigue, etc.) in a given patient.
  2. Specific brain regions where enhanced microglial activation is present underlie a portion of phenotypic variance in neuropsychiatric patients
  3. Combinations of neuropsychiatric phenotypes rather than specific differences in immune mechanisms underlie the contribution of central immune activation to a specific neuropsychiatric diagnosis.

The following measures will be obtained:

  1. microglial activation as quantified by PET using the radiotracer [11C]PBR-28 or [11C]ER176. ([11C]PBR-28 and [11C]ER176 specifically bind translocator protein (TSPO), which is associated with microglial activation and can thus serve as an in vivo biomarker of microglial activation and neuroinflammation. TSPO is also called the peripheral benzodiazepine receptor (PBR))
  2. dimension of specific neuropsychiatric symptoms (Hamilton Depression Rating Scale (HDRS), Montreal Cognitive Assessment (MoCA), Positive and Negative Affect Schedule (PANAS))
  3. presence/absence of a specific neuropsychiatric diagnosis (Dementing Illnesses, Traumatic Brain Injury, Major Depression, Bipolar Disorder, Pain Syndromes, Other Affective Disorders, etc.)

Using the above measures, correlations (and brain regional correlations) between the extent of microglial activation and the presence of a dimension of neuropsychiatric symptoms will be tested for. Following this, the presence of microglial activation (and brain regional microglial activation) 1) between healthy control volunteers and volunteers with neuropsychiatric syndromes and 2) between the various neuropsychiatric syndromes/diagnoses will be tested for.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Identifying Correlates of Brain Microglial Activation in Neuropsychiatric Syndromes: A Dimensional Approach
Actual Study Start Date : May 1, 2017
Estimated Primary Completion Date : August 2028
Estimated Study Completion Date : August 2028
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: PET with radiotracer [11C]PBR-28 or [11C]ER176
PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning.
 Drug: PET with radiotracer [11C]PBR-28 ( or [11C]ER176)
[11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning.
Other Name: [O-methyl-11C]N-acetyl-N-(2-methoxybenzyl)-2-phenoxy- 5-pyridinamine
Experimental: PET with radiotracer [11C]PBR-28 or [11C]ER176 and affective challenge
PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.
 Drug: PET with radiotracer [11C]PBR-28 ( or [11C]ER176)
[11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning.
Other Name: [O-methyl-11C]N-acetyl-N-(2-methoxybenzyl)-2-phenoxy- 5-pyridinamine

Other: Affective challenge
Affective challenge is the induction of, for example, mood or affective pain.
Other Name: biobehavioral challenges


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Level of TSPO expression as quantified by PET imaging to detect binding of the TSPO radiotracer [11C]PBR-28 [ Time Frame: obtained during PET scanning (between 1:30 PM and 3 PM) at study baseline within a few days of study enrollment ]

Secondary Outcome Measures :
  1. Affect as measured by the Hamilton Depression Rating Scale (HDRS) [ Time Frame: within 1-2 hours before PETobtained during PET scanning (between 1:30 PM and 3 PM) at study baseline within a few days of study enrollment ]
    HDRS is a multiple item questionnaire used to provide an indication of depression. A score of 0-7 is considered to be normal. Scores of 20 or higher indicate moderate, severe, or very severe depression.

  2. Mental Status as measured by the Montreal Cognitive Assessment (MoCA) [ Time Frame: within 1-2 hours before PETobtained during PET scanning (between 1:30 PM and 3 PM) at study baseline within a few days of study enrollment ]
    The MoCA assesses several cognitive domains. The total possible score is 30 points with a score of 26 or more considered normal.

  3. Affect as measured by the Positive and Negative Affect Schedule (PANAS) [ Time Frame: within 1-2 hours before PETobtained during PET scanning (between 1:30 PM and 3 PM) at study baseline within a few days of study enrollment ]
    Positive Affect Score: Scores can range from 10 - 50, with higher scores representing higher levels of positive affect. Negative Affect Score: Scores can range from 10 - 50, with lower scores representing lower levels of negative affect.

  4. Affect as measured by the Positive and Negative Affect Schedule (PANAS) [ Time Frame: during PET (between 1:30 PM and 3 PM)obtained during PET scanning (between 1:30 PM and 3 PM) at study baseline within a few days of study enrollment ]
    Positive Affect Score: Scores can range from 10 - 50, with higher scores representing higher levels of positive affect. Negative Affect Score: Scores can range from 10 - 50, with lower scores representing lower levels of negative affect.

  5. Affect as measured by the Positive and Negative Affect Schedule (PANAS) [ Time Frame: immediately following PET (3PM +/- 30 minutes)obtained during PET scanning (between 1:30 PM and 3 PM) at study baseline within a few days of study enrollment ]
    Positive Affect Score: Scores can range from 10 - 50, with higher scores representing higher levels of positive affect. Negative Affect Score: Scores can range from 10 - 50, with lower scores representing lower levels of negative affect.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must be between 18-45 years old
  • Males or females
  • Must be right handed
  • Must be able to sit unaccompanied for long periods of time with little body movement
  • Must be illicit drug free at time of scanning as appropriate (UDS negative),
  • Must be either healthy (without medical, neurological, psychiatric illness) or have a diagnosis of a neuropsychiatric syndrome (mood disorder, chronic pain syndrome, dementias, traumatic brain injury, substance/alcohol use disorder).
  • Healthy Control volunteers must be medication free (≥ 14 days)
  • Illicit drug free at time of scanning (verified by negative urine drug screen)

Exclusion Criteria:

  • Must not be a smoker.
  • Females must not be pregnant or nursing.
  • Must not suffer from claustrophobia
  • Must not meet exclusion criteria for MRI scanning (i.e. non-fixed magnetisable objects)
  • Must not be PBR-28 low affinity binder (or using the [11C]ER176 study radiotracer)
  • Healthy control volunteers must not have on-going, chronic, or relapsing/remitting medical, psychiatric (absence of both DSM-IV Axis I and/or Axis II disorders), or neurological illness as determined by combination of history, medical record, and/or examination.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03705715


Contacts
Layout table for location contacts
Contact: Alan Prossin, MBBS 713-486-2836 alan.prossin@uth.tmc.edu

Locations
Layout table for location information
United States, Texas
BBSB at UTHealth Recruiting
Houston, Texas, United States, 77054
Contact: alan R Prossin, MBBS    713-486-2836    alan.prossin@uth.tmc.edu   
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Investigators
Layout table for investigator information
Principal Investigator: Alan Prossin, MBBS The University of Texas Health Science Center, Houston
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Alan Prossin, Assistant Professor, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT03705715    
Other Study ID Numbers: HSC-MS-15-0744
First Posted: October 15, 2018    Key Record Dates
Last Update Posted: October 5, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alan Prossin, The University of Texas Health Science Center, Houston:
Microglial activation
Immune activation
PET neuroimaging
Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Disease
Pathologic Processes